These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 32393215

  • 1. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.
    Donohue JF, Kerwin E, Barnes CN, Moran EJ, Haumann B, Crater GD.
    BMC Pulm Med; 2020 May 11; 20(1):134. PubMed ID: 32393215
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials.
    Sethi S, Donohue JF, Ferguson GT, Barnes CN, Crater GD.
    Ther Adv Respir Dis; 2020 May 11; 14():1753466620905278. PubMed ID: 32106777
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
    Quinn D, Barnes CN, Yates W, Bourdet DL, Moran EJ, Potgieter P, Nicholls A, Haumann B, Singh D.
    Pulm Pharmacol Ther; 2018 Feb 11; 48():71-79. PubMed ID: 28987804
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.
    Donohue JF, Kerwin E, Sethi S, Haumann B, Pendyala S, Dean L, Barnes CN, Moran EJ, Crater G.
    Respir Med; 2019 Jul 11; 153():38-43. PubMed ID: 31150963
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
    D'Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF, AUGMENT COPD study investigators.
    Respir Res; 2014 Oct 14; 15(1):123. PubMed ID: 25756831
    [Abstract] [Full Text] [Related]

  • 10. Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease.
    Hvisdas C.
    Am J Health Syst Pharm; 2021 Jun 23; 78(13):1184-1194. PubMed ID: 33821890
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4.
    Ohar J, Tosiello R, Goodin T, Sanjar S.
    Int J Chron Obstruct Pulmon Dis; 2019 Jun 23; 14():27-37. PubMed ID: 30587959
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.
    D'Urzo AD, Singh D, Donohue JF, Kerwin EM, Ribera A, Molins E, Chuecos F, Jarreta D, Gil EG.
    Int J Chron Obstruct Pulmon Dis; 2019 Jun 23; 14():479-491. PubMed ID: 30880938
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial.
    Vogelmeier CF, Jones PW, Kerwin EM, Boucot IH, Maltais F, Tombs L, Compton C, Lipson DA, Bjermer LH.
    Respir Res; 2021 Oct 28; 22(1):279. PubMed ID: 34711232
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.
    Ray R, Tombs L, Naya I, Compton C, Lipson DA, Boucot I.
    Pulm Pharmacol Ther; 2019 Aug 28; 57():101802. PubMed ID: 31096036
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.
    Jones PW, Rennard SI, Agusti A, Chanez P, Magnussen H, Fabbri L, Donohue JF, Bateman ED, Gross NJ, Lamarca R, Caracta C, Gil EG.
    Respir Res; 2011 Apr 26; 12(1):55. PubMed ID: 21518460
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D, LANTERN Investigators.
    Int J Chron Obstruct Pulmon Dis; 2015 Apr 26; 10():1015-26. PubMed ID: 26082625
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials.
    Donohue JF, Feldman G, Sethi S, Barnes CN, Pendyala S, Bourdet D, Crater G.
    Pulm Pharmacol Ther; 2019 Aug 26; 57():101808. PubMed ID: 31152911
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.